Could a simple fat supplement protect preemie lungs?

NCT ID NCT07652684

Recruiting now Disease control Sponsor: Aristotle University Of Thessaloniki Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial investigates whether giving very preterm infants (born at 24-29 weeks) a daily supplement of two fatty acids—ARA and DHA—starting within three days of birth can reduce their risk of bronchopulmonary dysplasia (BPD), a chronic lung disease common in premature babies. Half of the infants receive the supplement along with standard care, while the other half receive standard care alone. The study tracks whether babies still need oxygen or breathing support at 36 weeks adjusted age.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ARA and DHA (fatty acids)
What this could lead to: If it works, this simple nutritional supplement could lower the risk of chronic lung disease in extremely preterm babies, reducing lifelong breathing problems.
What could go wrong: This is a small, early-phase trial (74 infants) at a single hospital. The supplement may not prevent BPD, and results may not apply to all preterm infants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHOPULMONARY DYSPLASIA (BPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchopulmonary dysplasia Premature Birth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRONCHOPULMONARY DYSPLASIA (BPD)

Contacts and locations

Locations

Papageorgiou General Hospital
RECRUITING

Thessaloniki, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.